Prosecution Insights
Prosecution Insights
5 pending office actions • 2 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SEAMAN, D MARGARET M | 1 | 76.6% | +8.0% |
| RZECZYCKI, PHILLIP MATTHEW | 1 | 62.7% | +39.6% |
| WEIDNER, ADAM M | 1 | 63.6% | +34.2% |
| JAVANMARD, SAHAR | 1 | 65.3% | +34.8% |
| ESSEX, LAURA ANN | 1 | 59.6% | +36.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17878121 | USE OF RILUZOLE, RILUZOLE PRODRUGS OR RILUZOLE ANALOGS WITH IMMUNOTHERAPIES TO TREAT CANCERS | JAVANMARD, SAHAR | 23d overdue |
| 18261419 | USE OF RILUZOLE PRODRUGS TO TREAT ALZHEIMER'S DISEASE | WEIDNER, ADAM M | 6d |
| 17268072 | USE OF RILUZOLE ORAL DISINTIGRATING TABLETS FOR TREATING DISEASES | ESSEX, LAURA ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17878121 | USE OF RILUZOLE, RILUZOLE PRODRUGS OR RILUZOLE ANALOGS WITH IMMUNOTHERAPIES TO TREAT CANCERS | JAVANMARD, SAHAR | 23d overdue |
| 18261419 | USE OF RILUZOLE PRODRUGS TO TREAT ALZHEIMER'S DISEASE | WEIDNER, ADAM M | 6d |
| 18726772 | PYRAZOLO[1,5-A]PYRIDIN-2,3-YL AMIDES AS KV7 CHANNEL ACTIVATORS | RZECZYCKI, PHILLIP MATTHEW | — |
| 17268072 | USE OF RILUZOLE ORAL DISINTIGRATING TABLETS FOR TREATING DISEASES | ESSEX, LAURA ANN | — |
| Art Unit | Apps |
|---|---|
| 1675 | 2 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18839860 | PYRAZOLYL COMPOUNDS AS KV7 CHANNEL ACTIVATORS | SEAMAN, D MARGARET M | — | §102DP | Non-Final OA | — | Pending | Aug 20, 2024 |
| 18726772 | PYRAZOLO[1,5-A]PYRIDIN-2,3-YL AMIDES AS KV7 CHANNEL ACTIVATORS | RZECZYCKI, PHILLIP MATTHEW | — | DP | Non-Final OA | — | Pending | Jul 03, 2024 |
| 18261419 | USE OF RILUZOLE PRODRUGS TO TREAT ALZHEIMER'S DISEASE | WEIDNER, ADAM M | 1675 | §102§103§112Other | Non-Final OA | 6d | Pending | Jul 13, 2023 |
| 17878121 | USE OF RILUZOLE, RILUZOLE PRODRUGS OR RILUZOLE ANALOGS WITH IMMUNOTHERAPIES TO TREAT CANCERS | JAVANMARD, SAHAR | 1622 | §102§103§112Other | Final Rejection | 23d overdue | Pending | Aug 01, 2022 |
| 17268072 | USE OF RILUZOLE ORAL DISINTIGRATING TABLETS FOR TREATING DISEASES | ESSEX, LAURA ANN | 1675 | §102§103 | Final Rejection | — | Pending | Feb 11, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial